Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer

Launched by FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · Sep 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict the outcomes of surgery for patients with colorectal cancer. Researchers are developing a model that combines imaging tests and metabolism data to help doctors understand how well a patient's cancer might respond to treatment. This information could assist in creating a more personalized treatment plan for each patient.

To be eligible for this trial, participants should be at least 18 years old, have been diagnosed with a gastrointestinal tumor, and plan to have surgery as recommended by their doctor. They will need to give their consent and agree to a biopsy, which is a procedure to collect tissue from the tumor. Participants can expect to undergo various imaging tests and provide samples for analysis. It's important to note that individuals with certain conditions, such as active cancer spread to other organs or those who are pregnant, cannot participate. This study is currently active but not recruiting new participants at this time.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • met the diagnostic criteria for gastrointestinal tumours;
• • age \>18 years;
• • planned to undergo surgery for gastrointestinal tumours according to the guidelines;
• • signed an informed consent form; and e) agreed to undergo a biopsy in order to collect tissue from the tumour lesion.
• Exclusion criteria:
• • contraindications to imaging;
• • withdrawal from the study cohort midway;
• • metastatic foci in the liver, lung or other distant organs confirmed by CT, MRI or ultrasound imaging;
• • gastrointestinal tumours combined with haemorrhage, obstruction or perforation;
• • women who were pregnant, breastfeeding or planning to become pregnant during the study period.